Cuppens K, Baas P, Geerdens E, Cruys B, et al. HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. Lung Cancer 2022;170:1-10.
PMID: 35689896